Valion Bio, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Valion Bio, Inc. (VBIO) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$3.43 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2025-08-14
- Valion Bio, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$1.93M.
- Valion Bio, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was -$1.50M.
- Valion Bio, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was -$1.48M.
- Valion Bio, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was -$1.43M.
- Valion Bio, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$5.66M.
- Valion Bio, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$8.24M.
- Valion Bio, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$10.10M.
- Valion Bio, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$8.49M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 1 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | -$1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$3.43M 10-Q · filed 2025-08-14 | -$4.91M derived: sum of 3 quarters · filed 2025-08-14 | -$6.34M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2025-03-31 | -$1.50M 10-Q · filed 2025-05-15 | -$2.98M derived: sum of 2 quarters · filed 2025-05-15 | -$4.41M derived: sum of 3 quarters · filed 2025-05-15 | -$5.68M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-12-31 | -$1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$2.91M derived: sum of 2 quarters · filed 2025-03-21 | -$4.17M derived: sum of 3 quarters · filed 2025-08-14 | -$5.66M 10-K · filed 2025-03-21 | |
| 2024-09-30 | -$1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$2.70M derived: sum of 2 quarters · filed 2025-08-14 | -$4.18M 10-Q · filed 2024-11-14 | -$6.42M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-06-30 | -$1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.75M 10-Q · filed 2025-08-14 | -$4.99M derived: sum of 3 quarters · filed 2025-08-14 | -$6.75M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$1.48M 10-Q · filed 2025-05-15 | -$3.72M derived: sum of 2 quarters · filed 2025-05-15 | -$5.48M derived: sum of 3 quarters · filed 2025-05-15 | -$7.61M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$4.00M derived: sum of 2 quarters · filed 2025-03-21 | -$6.13M derived: sum of 3 quarters · filed 2025-03-21 | -$8.24M 10-K · filed 2025-03-21 | |
| 2023-09-30 | -$1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$3.88M derived: sum of 2 quarters · filed 2024-11-14 | -$6.00M 10-Q · filed 2024-11-14 | -$8.26M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$4.24M 10-Q · filed 2024-08-14 | -$6.50M derived: sum of 3 quarters · filed 2024-08-14 | -$9.08M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$2.12M 10-Q · filed 2024-05-15 | -$4.37M derived: sum of 2 quarters · filed 2024-05-15 | -$6.95M derived: sum of 3 quarters · filed 2024-05-15 | -$9.97M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$4.84M derived: sum of 2 quarters · filed 2024-03-25 | -$7.86M derived: sum of 3 quarters · filed 2024-03-25 | -$10.10M 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$5.60M derived: sum of 2 quarters · filed 2023-11-14 | -$7.84M 10-Q · filed 2023-11-14 | -$11.57M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$3.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$5.26M 10-Q · filed 2023-08-14 | -$8.98M derived: sum of 3 quarters · filed 2023-08-14 | -$11.30M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$2.24M 10-Q · filed 2023-05-15 | -$5.96M derived: sum of 2 quarters · filed 2023-05-15 | -$8.28M derived: sum of 3 quarters · filed 2023-05-15 | -$9.38M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2022-01-31 | -$2.24M 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | -$3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$6.04M derived: sum of 2 quarters · filed 2023-03-31 | -$7.14M derived: sum of 3 quarters · filed 2023-03-31 | -$8.49M 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$3.41M derived: sum of 2 quarters · filed 2022-11-14 | -$4.77M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$2.45M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$1.36M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |